ArticleTranslational pediatrics2025
Optimal drug treatment for children with IgA vasculitis nephritis: a systematic review and network meta-analysis.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At present, there are many treatment options for childhood IgA vasculitis nephritis (IgAVN), but the optimal treatment method remains unclear, and high-quality evidence to guide treatment decisions is still limited. This study identifies the best drugs for childhood IgAVN via Bayesian network meta-analysis (NMA). Methods: PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, VIP, as well as Sinomed were comprehensively retrieved for pertinent randomized controlled trials (RCTs) examining various methods of treating childhood IgAVN with medication. NMA was enabled by R 4.2.2. The risk of bias was rated via the Cochrane Risk of Bias 2.0 (RoB 2.0). The effect size was estimated using the mean difference (MD), risk ratio (RR), or odds ratio (OR) and 95% confidence interval (CI). The effects of intervention methods were ranked using the surface under the cumulative ranking curve (SUCRA). The certainty of the evidence was examined via the Confidence in Network Meta-Analysis (CINeMA) approach. Possible publication bias was detected through funnel plots generated via Stata 18.0. Results: This study encompassed 73 RCTs. In comparison to standard of care (Soc), steroid therapy demonstrated the most favorable overall efficacy in IgAVN children (RR =1.17, 95% CI: 1.02-1.34). Leukotriene (LT) receptor antagonists were the most effective in reducing urinary protein (UP) levels (OR =13.28, 95% CI: 9.12-17.45)..Other therapies excelled in specific parameters. Conclusions: Steroids offer the most effective therapeutic approach for childhood IgAVN, though its safety profile needs further study. More research is required for clinical decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.